KNKenjiro Namikawa

Kenjiro Namikawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenjiro Namikawa has a total of 572 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Cutaneous Angiosarcoma in Japan: A 3‐Year Analysis of the Japan Skin Cancer Registry Study ( JSCaRS )

    by Hiroshi Kato, Fumitaka Ohno, Toshihiko Hoashi, Yuki Yamamoto, Yasuhiro Fujisawa, Eiji Nakano, Toshio Ichiki, Shuichi Ohe, Aya Maekawa, Koji Yoshino, et al.

    Nationwide prospective data on the clinical management of cutaneous angiosarcoma in Japan are lacking. We analyzed 3 years of data from the Japan Skin Cancer Registry Study, a registry involving 86 institutions. Analyses were restricted to the 335 patients registered at least 12 months before the follow‐up data cutoff, a criterion independent of outcome. The median age was 79 years, 66.6% were male, and 74.0% of lesions were located on the scalp. The median tumor diameter was 8.0 cm. At diagnosis, lymph node and distant metastases were present in 14.0% and 12.5%, respectively. Radiotherapy was administered to 78.8%, systemic therapy to 72.8%, and surgery to 14.6%. The most common treatment combination was radiotherapy plus systemic therapy without surgery (54.6%). Median overall survival was 29.0 months, with 1‐ and 2‐year survival rates of 73.8% and 54.8%, respectively. Overall survival was 33.0 months without metastasis, 20.0 months with lymph node metastasis, and 10.0 months with distant metastasis. Distant metastasis (hazard ratio 2.66; 95% confidence interval 1.63–4.33), tumor diameter (1.70 per unit of log‐transformed diameter; 1.30–2.22), and age (1.03 per year; 1.01–1.05) were independent prognostic factors; lymph node metastasis (1.59; 0.96–2.61) and male sex (1.46; 0.96–2.22) were not. Two‐year overall survival was higher in the surgery group (81.5% vs. 49.6%), but was no longer statistically significant after 1:1 propensity score matching (79.7% vs. 61.6%; hazard ratio 0.53; 0.24–1.20), although survival remained numerically higher in the surgery group. The objective response rate to systemic therapy declined from 57.7% in the first line to 23.0% in the second line and 6.7% in the third line. In Japan, cutaneous angiosarcoma is most commonly managed with radiotherapy and taxane‐based systemic therapy rather than surgery. The survival advantage in the unadjusted analysis may partly reflect imbalances in background factors and selection of patients with a favorable prognosis for surgery.

  • Open Access

    Association of pretreatment immune microenvironment profile with boron neutron capture therapy efficacy in cutaneous tumors: results from an ancillary multiplex immunofluorescence study

    by Masahiro Ueno, Tairo Kashihara, Satoshi Nakamura, Hana Endo, Taisuke Mori, Satsuki Kishikawa, Eiji Nakano, Dai Ogata, Kenjiro Namikawa, Naoya Yamazaki, et al.

    Boron neutron capture therapy (BNCT), an emerging novel radiotherapy modality, has shown immunological relevance in preclinical models. Although the safety and efficacy of BNCT for cutaneous tumors have been evaluated in a Phase I clinical trial, studies using human clinical specimens remain limited. In this exploratory translational study, we aimed to investigate pretreatment immune microenvironmental features in patients treated with BNCT and to descriptively assess their relationship with clinical response. To this end, formalin-fixed paraffin-embedded pretreatment biopsy samples obtained from a Phase I clinical trial of BNCT for cutaneous tumors were analyzed in three responders and three non-responders. Multiplex immunofluorescent staining was performed using CD8+ T-cell and dendritic cell (DC) antibody panels to assess the phenotypes and spatial relationships of immune cells within the tumor microenvironment. At baseline, responders tended to show higher densities of total T cells, CD8+ T cells, DCs and mature DC-like cells than non-responders. CD8+ T cells in responders tended to include higher proportions of granzyme B+ and programmed cell death protein 1-positive cells, and spatial analysis showed closer proximity between CD8+ T cells and mature DC-like cells. In contrast, the proportions of programmed death-ligand 1-positive cells among DCs and tumor cells were higher in non-responders than in responders. These descriptive findings suggest that pretreatment immune microenvironmental features may warrant further investigation as potential factors related to clinical response to BNCT.

  • Extramammary Paget disease with bilateral sentinel lymph node biopsy: a multicentre study of lymphatic patterns and outcomes

    by Yoshiki Sakai, Eiji Nakano, Ken Horisaki, Shoichiro Mori, Yuta Kage, Dai Ogata, Shusuke Yoshikawa, Masashi Akiyama, Naoya Yamazaki, Kenjiro Namikawa

    Background: Extramammary Paget disease (EMPD) can metastasize to lymph nodes or distant sites. Sentinel lymph node biopsy (SLNB) is recommended for invasive EMPD without clinical nodal involvement. Objectives: Lesions near or across the midline may show bilateral lymphatic drainage, but the clinical significance of bilateral SLNB remains unclear. This study evaluated the metastatic distribution of sentinel lymph nodes (SLNs) and its association with clinicopathological features, lymphatic drainage patterns and survival in patients undergoing bilateral SLNB. Methods: We retrospectively reviewed 147 patients with EMPD who underwent bilateral SLNB at three institutions between 2015 and 2025. Tumour characteristics, SLN status, recurrence and survival outcomes were analysed. Patients were stratified as bilateral negative, unilateral positive or bilateral positive. Clinicopathological features, lymphatic drainage patterns and survival outcomes were compared, including overall survival, recurrence-free survival (RFS) and disease-free survival (DFS). Results: Bilateral SLN positivity was detected in eight male patients with genital nodular lesions. Unilateral positivity occurred in 12 patients, and 127 were bilaterally negative. Contralateral SLNs were frequently negative despite lesions crossing the midline, although bilateral metastases developed in two patients. Four ectopic lower-abdominal lesions were identified, two with irregular drainage. Patients with bilaterally negative SLNs had significantly better survival than those with SLN metastases. No significant differences in RFS or DFS were observed between the unilateral- and bilateral-positive groups. Conclusions: Bilateral SLN positivity is rare and limited to male genital cases. It was not associated with worse disease-related outcomes than unilateral positivity. Risk of bilateral metastasis appears to depend more on tumour location than intrinsic aggressiveness.

  • Open Access

    Figure 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Risk for recurrence based on ctDNA detection during surveillance. Overall observed rate of relapse at data cutoff (A and B) and Kaplan–Meier estimates of probability of recurrence over time (C and D) by anatomic site based on longitudinal ctDNA detection after surgery. A and C, Never detected; (B and D) ever detected. Three patients with detectable ctDNA before or during adjuvant therapy cleared ctDNA at later timepoints without recurrence.

  • Open Access

    Figure 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Detectable ctDNA during surveillance is associated with higher risk for recurrence and death from melanoma. Kaplan–Meier estimates of probability of distant recurrence (A), any recurrence (B), or OS (C) based on whether ctDNA was ever or never detected during longitudinal surveillance after surgery. HRs and P values corresponding to the landmark survival analysis at 12, 18, and 24 months after surgery can be found in Supplementary Table S4.

  • Open Access

    Data from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival (OS) benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molecular residual disease (MRD) assays may influence management. We validated a tissue-free MRD assay in 48 patients with clinical stage II to III melanoma treated with surgery (52% nonacral cutaneous, 31% acral, and 17% mucosal). The assay detects MRD through bioinformatic analysis of methylation signals across >20,000 epigenomic regions. Plasma samples (n = 281; 280 successfully reported) were prospectively collected before surgery, at day 28, and every 3 to 6 months thereafter. Associations among MRD detection, recurrence, and OS were analyzed. At a median follow-up of 34.6 months with 27 recurrence events, postoperative surveillance sensitivity for distant recurrence was 81% with 100% posttreatment specificity. The median lead time between MRD detection and radiographic recurrence was 70.5 days. Surveillance MRD detection was associated with increased recurrence risk [hazard ratio (HR), 26.55; 95% confidence interval (CI), 2.86–246.58; P = 0.004]. Similarly, MRD detection 28 days postoperatively independently predicted recurrence (HR, 11.70; 95% CI, 3.09–43.76; P < 0.001) and death (HR, 31.14; 95% CI, 5.37–221.1; P < 0.001). Tissue-free epigenomic MRD detection was sensitive, specific, and significantly associated with recurrence and melanoma-related death. These findings support the use of this assay in melanoma as a rapid, noninvasive approach for earlier identification of patients at high risk for recurrence, enabling refined treatment and surveillance strategies. Significance:Prognostic tools for high-risk melanoma rely on baseline factors with limited dynamic risk assessment. A tissue-free MRD assay demonstrated high sensitivity and specificity for distant recurrence detection, identifying molecular relapse before radiographic recurrence. Postoperative MRD detection was strongly associated with recurrence and melanoma-related death, enabling refined treatment and surveillance strategies.

  • Open Access

    Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    CtDNA detection increases with surveillance sampling and is associated with lead time prior to recurrence. A, Kaplan–Meier estimate of cumulative sensitivity of ctDNA detection with serial sampling in patients with recurrence. B, Timing of first ctDNA detection (day 28 postoperatively, after day 28 but prior to recurrence, or at recurrence) among 27 patients with recurrence based on anatomic location of recurrence. C, The median lead time among 18 samples with ctDNA detected in patients with recurrence was 70.5 days (IQR, 22.8–140.8 days) but ranged up to 273 days. D, Kaplan–Meier estimate of cumulative probability of ctDNA detection in all patients with stage II–III melanoma.

  • Open Access

    Figure 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Swimmer plots depicting ctDNA results for patients included in the surveillance analysis. A, Patients with recurrence; (B) patients with no recurrence at data cutoff. pTNM, pathologic tumor–node–metastasis.

  • Open Access

    Figure 5 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Detectable ctDNA at day 28 after surgery is associated with higher risk for recurrence and death from melanoma. A, Cox proportional hazard analysis of clinical factors associated with recurrence (***, P < 0.0001; *, P < 0.05) and Kaplan–Meier estimates for (B) any recurrence, (C) distant recurrence, and (D) OS based on ctDNA detection 28 days after surgery. HRs and P values can be found in Supplementary Table S5.

  • Open Access

    Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)

    by Kenjiro Namikawa, Dai Ogata, Eiji Nakano, Naoya Yamazaki, Azusa Komada, Akira Takahashi, Shusuke Yoshikawa, Chiemi Notake, Ryuta Mitani, Takayuki Yoshino, et al.

    Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)